Skip to main content
SpringerLink
Log in

Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence

  • Chapter
  • First Online:
Blistering Diseases

Abstract

Corticosteroids are central to the management of autoimmune blistering diseases. They can be used in intravenous formulations for acute management of life-threatening disease, systemic oral formulations for moderate to severe disease, and topical therapy for mild disease or mucosal involvement. This chapter examines the available evidence for corticosteroid use in autoimmune blistering diseases and also examines the adverse effects associated with corticosteroid use. The aim in using corticosteroids in diseases such as pemphigus and bullous pemphigoid is to achieve adequate disease control whilst minimizing adverse outcomes caused by therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bikowski J, Pillai R, et al. The position not the presence of the halogen in corticosteroids influences potency and side effects. Drugs Dermatol. 2006;5(2):125–30.

    Google Scholar 

  2. Williams LC, Nesbitt Jr LT. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin. 2001;19(1):63–77.

    Article  CAS  PubMed  Google Scholar 

  3. McClain R, Yentzer B, Fledman S. Comparison of skin concentration following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses. Drugs Dermatol. 2009;8(12):1076–9.

    Google Scholar 

  4. Tóth G, Westerlaken B, Eilders M, et al. Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacol. 2002;36:1109.

    Article  Google Scholar 

  5. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points and therapeutic response for pemphigus. JAAD. 2008;58(6):1043–6.

    Article  Google Scholar 

  6. Murrell DF, Daniel B, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. JAAD. 2012;66(3):479–85.

    Article  Google Scholar 

  7. Martin L, Agero A-L, Werth V et al. Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus (Review). Cochrane Database Syst Rev. 2009;(1):CD006263.

    Google Scholar 

  8. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926–37.

    Article  CAS  PubMed  Google Scholar 

  9. Ratnam K, Phay K, Tan C. Pemphigus therapy with oral prednisolone regimens: a five year study. Int J Dermatol. 1990;29:363–7.

    Article  CAS  PubMed  Google Scholar 

  10. Mentink L, Mackenzie M, Toth G, et al. Randomized control trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris. Arch Dermatol. 2006;143:570–6.

    Google Scholar 

  11. Lapiere K, Caers S, Lambert J. A case of long standing pemphigus vulgaris on the scalp. Dermatology. 2004;209:162–3.

    Article  PubMed  Google Scholar 

  12. Baykal C, Azizlerli G, Thoma-Uszynski S, et al. Pemphigus vulgaris localized to the nose and cheeks. J Am Acad Dermatol. 2002;47:875–8.

    Article  PubMed  Google Scholar 

  13. Dagistan S, Goregen M, Miloglu O, et al. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci. 2008;50(3):359–62.

    Article  PubMed  Google Scholar 

  14. Kirtschig G, Middleton P, Bennett C Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.

    Google Scholar 

  15. Parker S, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol. 2011;29(1):69–79.

    Article  PubMed  Google Scholar 

  16. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111(10):925–8.

    CAS  PubMed  Google Scholar 

  17. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120:518–21.

    CAS  PubMed  Google Scholar 

  18. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.

    Article  CAS  PubMed  Google Scholar 

  19. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681–7.

    Article  CAS  PubMed  Google Scholar 

  20. Knudson RM, Kalaaj AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther. 2010;23(3):268–80.

    Article  PubMed  Google Scholar 

  21. Kirtschig G, Murrell D, Wojnarowska F, et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev. 2003;(1):CD004056.

    Google Scholar 

  22. Korman N. Linear IgA bullous dermatosis. In: Lebwohl M, Heymann W, Berth-Jones J, Coulson I, editors. Treatment of skin disease. Comprehensive therapeutic strategies. 2nd ed. Philadelphia: Mosby/Elsevier Ltd; 2006. p. 358–60.

    Google Scholar 

  23. Shimizu S, Natsuga K, Shinkuma S, et al. Localized linear IgA/IgG bullous dermatosis. Acta Derm Venereol. 2010;90:621–4.

    Article  PubMed  Google Scholar 

  24. Kirtschig G, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database of Syst Rev. 2000;(4):CD004056.

    Google Scholar 

  25. Ishii N, Takahiro Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what’s new? J Dermatol. 2010;37:220–30.

    Article  PubMed  Google Scholar 

  26. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol. 1999;24(4):255–9.

    Article  CAS  PubMed  Google Scholar 

  27. Hanna A, Deshan Sebaratnam DF, Chee S, et al. Development of a disease-specific quality of life instrument for autoimmune bullous dermatoses: the ABQOL. J Invest Dermatol. 2011;131:S33.

    Google Scholar 

  28. Mendiratta V, Khan A, Solanki RS. Avascular necrosis: a rare complication of steroid therapy for pemphigus. Indian J Dermatol. 2008;53:28–30.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14:199–206.

    CAS  PubMed  Google Scholar 

  30. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82–8.

    Article  CAS  PubMed  Google Scholar 

  31. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70mg in patients with glucocorticoid induced bone loss: a 12 month randomizes, placebo controlled clinical trial. J Rheumatol. 2009;36(8):1705–14.

    Article  CAS  PubMed  Google Scholar 

  32. Cohen S, Levy R, Keller M, et al. Risendronate therapy prevents corticosteroid induced bone loss: a twelve month, multicenter, randomized, double blind placebo controlled parallel group study. Arthritis Rheumatol. 1999;42(11):2309–18.

    Article  CAS  Google Scholar 

  33. Minden S, Orav J, Schildkraut J. Hypomanic reactions to ACTH and prednisone in treatment for multiple sclerosis. Neurology. 1988;38(10):1631–4.

    Article  CAS  PubMed  Google Scholar 

  34. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects. Drug Saf. 2000;22(2):111–22.

    Article  CAS  PubMed  Google Scholar 

  35. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61(1):104–7.

    Article  PubMed  Google Scholar 

  36. Keenan P, Jacobson M, Soleymani R, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47((6):1396–402.

    Article  Google Scholar 

  37. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol. 1994;21(7):1207–13.

    CAS  PubMed  Google Scholar 

  38. Trikudanathan S, McMahon GT. Optimum management of glucocorticoid treated patients. Nat Rev Endocrinol. 2008;4:62–271.

    Google Scholar 

  39. Souverein P, Berars A, Van Staa T. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089–93.

    Article  CAS  PubMed  Google Scholar 

  41. Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2009;8(3), CD007346.

    Google Scholar 

  42. Lehman JS, Murrell DF, Camilleri MJ, et al. Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin. 2011;29(4):591–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Prince Alfred Hospital, Sydney, NSW, Australia

    John W. Frew MBBS (Hons), MMed (Clin Epi)

  2. Department of Dermatology, St. George Hospital, University of NSW Medical School, Sydney, NSW, Australia

    Dédée F. Murrell MA(Camb),BMBCh(Oxf),FAAD,MD,FACD,FRCP

Authors
  1. John W. Frew MBBS (Hons), MMed (Clin Epi)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dédée F. Murrell MA(Camb),BMBCh(Oxf),FAAD,MD,FACD,FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dédée F. Murrell MA(Camb),BMBCh(Oxf),FAAD,MD,FACD,FRCP .

Editor information

Editors and Affiliations

  1. Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia

    Dédée F. Murrell

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Frew, J.W., Murrell, D.F. (2015). Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence. In: Murrell, D. (eds) Blistering Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45698-9_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45698-9_46

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45697-2

  • Online ISBN: 978-3-662-45698-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation